PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...

Study findings support PSMA-PET as a first-line approach for the primary staging of intermediate- to high-risk prostate cancer. In head-to-head comparisons, prostate-specific membrane antigen positron ...

A molecular imaging tool developed by researchers at the University of California’s two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer ...

It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

SYDNEY, March 31, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...

Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine (18F) or PSMA (68Ga) PET/CT for target dose-escalation. This is an ASCO Meeting ...

Dec. 30, 2024 3:45 PM ETTelix Pharmaceuticals Limited (TLX) In the publication, the investigators report initial results based on a study of 40 patients in six countries 5, who received TLX599-CDx ...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 ...